A CLINICAL STUDY OF MARKET SAMPLES OF NAGAKESARA IN THE MANAGEMENT OF POLY CYSTIC OVARIAN DISEASE (PCOD)

Abstract

This study was conducted to evaluate the efficacy of different market samples of Nagakesara in cases of PCOD. In this study 30 patients were divided into 3 groups. Group 1: MF Group (Mesua ferrea Linn. powder with milk), Group 2: OL Group (Ochrocarpus longifolium Benth & Hook. f; powder with milk), Group 3: CT Group (Cinnamomum tamala Nees & Ebern powder with milk) and advocated the trial drug with a dosage of 40-50mg/kg body weight per day for a duration of 3months with a follow up of every 15days. Subjective parameters like duration of menstruation, gap between two cycles, pain during menstruation, quantity of menstrual bleeding, Acne, Hirsutism, Acanthosis nigracans, Obesity are taken and results were analyzed statistically before and after treatment. Group 1 showed that 10% of the patients recovered completely, 55.09% recovered moderately and 35% remains unchanged. Group 2 showed that 10% of the patients recovered completely, 45.66% moderately and 44% remains unchanged. Group 3 showed that 0% of the patients recovered completely, 52% recovered moderately and 48% remains unchanged. Mesua ferrea showed extremely significant result i.e., P<0.001 in duration of menstruation (67.85%), gap between two cycles (65.62%), quantity of menstrual bleeding (66.66%). All the observations related to the total effect of therapy suggests that patients of Group 1 were well responded to the therapy than the patients of Group 2 and Group 3. Conclusion: The present comparative clinical study shows that the Amapachana property, the capacity to induce ovulation and reduction in the clinical features are more clearly observed in Mesua ferrea Linn. than in others.